Software Validation in Digital Health Devices

Authors

  • Andreas Muller Author
  • Sofia Popescu Author
  • Sofia Garcia Author

DOI:

https://doi.org/10.5281/zenodo.19610455

Keywords:

software validation; digital health; SaMD; IEC 62304; AI/ML; automated testing; formal verification; real-world performance; continuous integration; post-market surveillance

Abstract

Software validation in digital health devices -- the documented evidence that software performs as intended and is fit for its intended use in the device's operating environment -- has become one of the most resource-intensive activities in medical device development as software increasingly constitutes the primary functional component of diagnostic, therapeutic, and monitoring devices. The FDA's 2022 guidance on software as a medical device (SaMD) and the EU MDR Annex I GSPR 17 have elevated software validation expectations, requiring risk-based validation strategies that scale validation depth with software risk classification, demonstrate ongoing software performance in post-market conditions, and address the unique validation challenges of AI/ML-based software that learns and updates after deployment. This study presents the Software Validation Assessment Framework for Digital Health Devices (SVAFDHD), evaluating five validation strategies -- risk-based static validation per IEC 62304, automated testing with continuous integration, model-based testing with formal verification, real-world performance validation, and AI-augmented test case generation -- across four digital health software categories: SaMD diagnostic algorithms, closed-loop therapeutic software, patient monitoring and alerting systems, and AI/ML-based clinical decision support. Our Software Validation Effectiveness Score (SVES) integrates defect detection coverage, validation efficiency, regulatory compliance, post-deployment performance assurance, and AI/ML validation capability. AI-augmented test case generation achieved the highest SVES (0.928) through neural network models that generated 10,000 adversarial test cases exposing edge-case failures invisible to manually designed tests, increasing defect detection coverage from 68% to 94%, while real-world performance validation achieved the highest post-deployment assurance (0.955) through continuous clinical performance monitoring that detected software performance drift in 4.2 months versus 14 months for periodic testing.

Downloads

Published

2026-08-16

How to Cite

Software Validation in Digital Health Devices. (2026). International Journal of Drug and Medical Device Research, 3(2), 65-72. https://doi.org/10.5281/zenodo.19610455

Similar Articles

11-20 of 99

You may also start an advanced similarity search for this article.